Real-world Drug Utilization and Treatment Patterns in Patients with Tenosynovial Giant Cell Tumors in the USA

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Feb 21

PMID 38380590

Authors

Charles Dharmani

Oluwatosin Fofah

Eric Wang

Maribel Salas

Margaret Wooddell

Nora Tu

Jenny Tse

Aimee Near

Gabriel Tinoco

Affiliations

Soon will be listed here.

Abstract

Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. To characterize drug utilization and treatment patterns in TGCT patients. In a retrospective observational study using IQVIA's linked prescription and medical claims databases (2018-2021), TGCT patients were stratified by their earliest systemic therapy claim (pexidartinib [N = 82] or non-FDA-approved systemic therapy [N = 263]). TGCT patients treated with pexidartinib versus non-FDA-approved systemic therapies were predominantly female (61 vs 50.6%) and their median age was 47 and 54 years, respectively. Pexidartinib-treated patients had the highest 12-month probability of remaining on treatment (54%); 34.1% of pexidartinib users had dose reduction after their first claim. This study provides new insights into the unmet need, utilization and treatment patterns of systemic therapies for the treatment of TGCT patients.

References

Verspoor F, van der Geest I, Vegt E, Veth R, van der Graaf W, Schreuder H . Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol. 2013; 9(10):1515-31. DOI: 10.2217/fon.13.124. View

Shenolikar R, Liu S, Shah A, Tse J, Cao Y, Near A . Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Med. 2022; 12(1):159-169. PMC: 9844647. DOI: 10.1002/cam4.4918. View

Van der Heijden L, Gibbons C, Hassan A, Kroep J, Gelderblom H, van Rijswijk C . A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal. J Surg Oncol. 2012; 107(4):433-45. DOI: 10.1002/jso.23220. View

Ushijima M, Hashimoto H, Tsuneyoshi M, Enjoji M . Giant cell tumor of the tendon sheath (nodular tenosynovitis). A study of 207 cases to compare the large joint group with the common digit group. Cancer. 1986; 57(4):875-84. DOI: 10.1002/1097-0142(19860215)57:4<875::aid-cncr2820570432>3.0.co;2-y. View

Fotiadis E, Papadopoulos A, Svarnas T, Akritopoulos P, Sachinis N, Chalidis B . Giant cell tumour of tendon sheath of the digits. A systematic review. Hand (N Y). 2012; 6(3):244-9. PMC: 3153624. DOI: 10.1007/s11552-011-9341-9. View

Sharma V, Cheng E . Outcomes after excision of pigmented villonodular synovitis of the knee. Clin Orthop Relat Res. 2009; 467(11):2852-8. PMC: 2758986. DOI: 10.1007/s11999-009-0922-7. View

Burton T, Ye X, Parker E, Bancroft T, Healey J . Burden of Illness Associated with Tenosynovial Giant Cell Tumors. Clin Ther. 2018; 40(4):593-602.e1. PMC: 7440779. DOI: 10.1016/j.clinthera.2018.03.001. View

Tap W, Wainberg Z, Anthony S, Ibrahim P, Zhang C, Healey J . Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015; 373(5):428-37. DOI: 10.1056/NEJMoa1411366. View

Vaynrub A, Healey J, Tap W, Vaynrub M . Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations. Onco Targets Ther. 2022; 15:53-66. PMC: 8763255. DOI: 10.2147/OTT.S345878. View

10.

Brahmi M, Cassier P, Dufresne A, Chabaud S, Karanian M, Meurgey A . Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). PLoS One. 2020; 15(5):e0233046. PMC: 7239463. DOI: 10.1371/journal.pone.0233046. View

11.

Gelderblom H, Wagner A, Tap W, Palmerini E, Wainberg Z, Desai J . Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2020; 127(6):884-893. PMC: 7946703. DOI: 10.1002/cncr.33312. View

12.

Ehrenstein V, Andersen S, Qazi I, Sankar N, Pedersen A, Sikorski R . Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark. J Rheumatol. 2017; 44(10):1476-1483. DOI: 10.3899/jrheum.160816. View

13.

Mastboom M, Verspoor F, Verschoor A, Uittenbogaard D, Nemeth B, Mastboom W . Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017; 88(6):688-694. PMC: 5694816. DOI: 10.1080/17453674.2017.1361126. View

14.

Staals E, Ferrari S, Donati D, Palmerini E . Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. Eur J Cancer. 2016; 63:34-40. DOI: 10.1016/j.ejca.2016.04.022. View

15.

Mastboom M, Palmerini E, Verspoor F, Rueten-Budde A, Stacchiotti S, Staals E . Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019; 20(6):877-886. DOI: 10.1016/S1470-2045(19)30100-7. View

16.

Myers B, MASI A . Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine (Baltimore). 1980; 59(3):223-38. View

17.

Tap W . ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020; 16(25):1875-1878. DOI: 10.2217/fon-2020-0307. View

18.

Verspoor F, Mastboom M, Hannink G, Maki R, Wagner A, Bompas E . Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Sci Rep. 2019; 9(1):14551. PMC: 6786996. DOI: 10.1038/s41598-019-51211-y. View

19.

Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S . Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018; 19(5):639-648. DOI: 10.1016/S1470-2045(18)30143-8. View

20.

Valle A, Piccaluga F, Potter H, Salvati E, Pusso R . Pigmented villonodular synovitis of the hip: 2- to 23-year followup study. Clin Orthop Relat Res. 2001; (388):187-99. DOI: 10.1097/00003086-200107000-00026. View